Hepatotoxicity Associated with Cisplatin Chemotherapy

Cersosimo, Robert J.

doi:10.1177/106002809302700408

Cited by 75 publications

(40 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, this model also permitted the assessment of whether MI and CY cause any interactions and/or reduce tumor development. Many chemotherapeutic agents and drug combinations are very toxic to patients; for example, doxorubicin-associated cardiotoxicity (Mackay et al 1994), the hepatotoxicity of cisplatin (Cavalli et al 1978;Cersosimo 1993;Pollera et al 1987) and the neurotoxicity of paclitaxel (Postma et al 1995). In this study, we verified that MI-treated mice did not display any reductions in body weight or show any other clinical manifestations of MI-induced toxicity, such as hair loss (Crounse et al 1962).…”

Section: Discussionsupporting

confidence: 61%

Mimosine and cyclophosphamide: a potential new combination therapy used to prevent tumor development

Dipe

Gotardo

Haraguchi³

et al. 2012

Braz. arch. biol. technol.

View full text Add to dashboard Cite

The effects of mimosine (MI), which is an amino acid that is derived from Leucaena leucocephala, were evaluated on the growth of ascitic Ehrlich tumors, and the effects of the combination treatment of MI and cyclophosphamide (CY) on tumor growth were also assessed. Mice were divided into groups that received the following treatments over the course of 20 days: phosphate buffer solution (CO), MI, Ehrlich cells (E), E plus CY (EC), E plus MI (EM) and E plus MI and CY (EMC). No signs of toxicity were detected in the mice from the MI group. The mice from the EMC group showed reductions in body weights when compared with those from the E group. The animals from the EC, EM and EMC groups showed reductions in ascitic volume

show abstract

Section: Discussionsupporting

confidence: 61%

Mimosine and cyclophosphamide: a potential new combination therapy used to prevent tumor development

Dipe

Gotardo

Haraguchi³

et al. 2012

Braz. arch. biol. technol.

View full text Add to dashboard Cite

show abstract

“…The DLT of acute hepatotoxicity occurred at dose level 150 mg; the patient presented the toxicity at the end of chemotherapy treatment when she was also taking erythromycin and antiemetics. Acute severe hepatitis, though rare, is occasionally observed with EGFR inhibitors gefitinib or erlotinib (33), cisplatin (34), and erythromycin (35). All medications were interrupted and the patient presented complete recovery.…”

Section: Discussionmentioning

confidence: 99%

Phase I Trial of Erlotinib Combined with Cisplatin and Radiotherapy for Patients with Locally Advanced Cervical Squamous Cell Cancer

Nogueira-Rodrigues

Carmo

Viégas

et al. 2008

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: This phase I trial was aimed to determine the maximum tolerated dose and related toxicity of erlotinib (E) when administered concurrently with standard chemoradiation (CRT) for cervical cancer. Experimental Design: In a modified Fibonacci design, the study aimed to study three cohorts of at least three patients receiving escalating doses of erlotinib (50/100/150 mg) combined with cisplatin (40 mg/m 2 , weekly, 5 cycles) and radiotherapy (external beam 4,500 cGy in 25 fractions, followed by 4 fractions/600 cGy/weekly of brachytherapy) in squamous cell cervical carcinoma patients, stage IIB to IIIB. Results: Fifteen patients were enrolled, 3 at dose level (DL) 50 mg, 4 at DL100 mg, and 8 at DL 150 mg. Patients presented median age 47 (36-59), stage IIB (46.2%) and IIIB (53.8%). Overall, E+CRT was well-tolerated. Three patients did not complete the planned schedule. One patient at DL 100 mg withdrew informed consent due to grade 2 rash; at DL 150 mg, 1 patient presented Raynaud's Syndrome and had C interrupted, and another patient presented grade 4 hepatotoxicity. The latter was interpreted as dose limiting toxicity and a new cohort of 150 mg was started. No further grade 4 toxicity occurred. Grade 3 toxicity occurred in 6 cases: diarrhea in 3 patients, rash in 2 patients, and leukopenia in 1 patient. E+CRT did not lead to limiting in-field toxicity. Conclusions: E+CRT is feasible to locally advanced squamous cell cervical cancer and is well tolerated.The maximum tolerated dose has been defined as150 mg.To the best of our knowledge, this is the first report of a combination of erlotinib, cisplatin, and pelvic radiotherapy.

show abstract

“…The nephrotoxicity and ototoxicity of cisplatin are the most common dose-limiting factors in cancer chemotherapy (47). Cisplatin hepatotoxicity rarely occurs at standard doses, but it is frequently seen after administration of highdose cisplatin and can alter the clinical situation of patients (3). Previous studies showed that elevated cytochrome P450 2E1 (CYP2E1) levels can enhance cisplatin-induced hepatotoxicity (36), and metallothionein (MT)-knockout mice are more sensitive to cisplatin hepatotoxicity (35).…”

mentioning

confidence: 99%

Hepatitis B Virus X Protein Enhances Cisplatin-Induced Hepatotoxicity via a Mechanism Involving Degradation of Mcl-1

Chen

Liang

et al. 2011

J Virol

View full text Add to dashboard Cite

show abstract

Hepatotoxicity Associated with Cisplatin Chemotherapy

Abstract: This patient may have experienced cisplatin-induced liver damage. Metoclopramide and ondansetron may have contributed to this effect.

Cited by 75 publications

References 11 publications

Mimosine and cyclophosphamide: a potential new combination therapy used to prevent tumor development

Mimosine and cyclophosphamide: a potential new combination therapy used to prevent tumor development

Phase I Trial of Erlotinib Combined with Cisplatin and Radiotherapy for Patients with Locally Advanced Cervical Squamous Cell Cancer

Hepatitis B Virus X Protein Enhances Cisplatin-Induced Hepatotoxicity via a Mechanism Involving Degradation of Mcl-1

Contact Info

Product

Resources

About